Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Nuclear receptors in renal disease.
Authors
Levi M
Submitted By
Moshe Levi on 2/22/2012
Status
Published
Journal
Biochimica et biophysica acta
Year
2011
Date Published
8/1/2011
Volume : Pages
1812 : 1061 - 1067
PubMed Reference
21511032
Abstract
Diabetes is the leading cause of end-stage renal disease in developed countries.
In spite of excellent glucose and blood pressure control, including
administration of angiotensin converting enzyme inhibitors and/or angiotensin II
receptor blockers, diabetic nephropathy still develops and progresses. The
development of additional protective therapeutic interventions is, therefore, a
major priority. Nuclear hormone receptors regulate carbohydrate metabolism,
lipid metabolism, the immune response, and inflammation. These receptors also
modulate the development of fibrosis. As a result of their diverse biological
effects, nuclear hormone receptors have become major pharmaceutical targets for
the treatment of metabolic diseases. The increasing prevalence of diabetic
nephropathy has led intense investigation into the role that nuclear hormone
receptors may have in slowing or preventing the progression of renal disease.
This role of nuclear hormone receptors would be associated with improvements in
metabolism, the immune response, and inflammation. Several nuclear receptor
activating ligands (agonists) have been shown to have a renal protective effect
in the context of diabetic nephropathy. This review will discuss the evidence
regarding the beneficial effects of the activation of several nuclear,
especially the vitamin D receptor (VDR), farnesoid X receptor (FXR), and
peroxisome-proliferator-associated receptors (PPARs) in preventing the
progression of diabetic nephropathy and describe how the discovery and
development of compounds that modulate the activity of nuclear hormone receptors
may provide potential additional therapeutic approaches in the management of
diabetic nephropathy. This article is part of a Special Issue entitled:
Translating nuclear receptors from health to disease.
Investigators with authorship
Name
Institution
Moshe Levi
Georgetown University
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!